Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Jairath V, et al. Among authors: feagan bg. Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD011572. doi: 10.1002/14651858.CD011572.pub2. Cochrane Database Syst Rev. 2017. PMID: 28886205 Free PMC article. Review.
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Sandborn WJ, et al. Among authors: feagan bg. Am J Gastroenterol. 2005 Aug;100(8):1780-7. doi: 10.1111/j.1572-0241.2005.41992.x. Am J Gastroenterol. 2005. PMID: 16086715 Clinical Trial.
Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Sandborn WJ, et al. Among authors: feagan bg. N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335. N Engl J Med. 2005. PMID: 16267322 Free article. Clinical Trial.
Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Rutgeerts P, et al. Among authors: feagan bg. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. N Engl J Med. 2005. PMID: 16339095 Free article. Clinical Trial.
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. D'Haens G, et al. Among authors: feagan bg. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038. Epub 2006 Dec 20. Gastroenterology. 2007. PMID: 17258735 Review. No abstract available.
492 results